Genepexpert reagents/panels
Ended Definitive Contract Awarded Last action
- Contract number
- W91YTZ22C0004
- Awardee
-
Cepheid UEI W6HQTMWB9Q28
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $259,355
Award facts
- Opportunity
-
- CEPHEID reagents/panels Special Notice · W91YTZ22Q0014 · Posted Feb 14, 2022
- Contract value 100% obligated
- $259,355.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- Funding agency
- Defense Health Agency Department of Defense
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Fort Gordon, GA 30905, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$228,314 | |
| Funding Only Action | $162,556 | |
| Exercise an Option | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $162,556 | |
| Original award | $162,556 |
About this award
The Defense Health Agency awarded a $259,355 firm fixed-price definitive contract to Cepheid for GeneXpert reagents and panels to support pathology operations at Dwight David Eisenhower Army Medical Center (formerly Fort Gordon) in Georgia. The contract, awarded May 1, 2022, with an ultimate completion date of April 30, 2025, was issued through sole source procurement using commercial item procedures without set-aside designation. The originating special notice, posted February 14, 2022, indicated the Regional Health Contracting Office – Atlantic's intent to provide GeneXpert molecular diagnostic reagents and panels to the medical center's clinical laboratory for the initial period of February 21, 2022 through February 20, 2023.
Cepheid, headquartered in Sunnyvale, California, is a specialized manufacturer of advanced molecular diagnostic systems and reagents for infectious disease detection. The company serves as a primary federal supplier to multiple defense and civilian healthcare agencies, with extensive experience providing GeneXpert diagnostic platforms and associated testing solutions. As a sole source award, this contract reflects the Defense Health Agency's reliance on Cepheid's specialized molecular diagnostic capabilities to support clinical laboratory testing requirements at military medical treatment facilities, consistent with the company's established role as a core supplier of diagnostic reagents and test kits across the federal healthcare system.
Quick answers
Who was awarded contract W91YTZ22C0004?
W91YTZ22C0004 was awarded to Cepheid by Medical Command (Department of the Army) on May 1, 2022.
How much is contract W91YTZ22C0004 worth?
The government has obligated $259,355 on W91YTZ22C0004.
Which agency awarded contract W91YTZ22C0004?
Medical Command (Department of the Army) awarded W91YTZ22C0004, with funding from Defense Health Agency (Department of Defense).
Was contract W91YTZ22C0004 competed?
The extent of competition for W91YTZ22C0004 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award